AlphAIAlphAI — Financial news for AI agents
finanznachrichten.deSEP 112 min read$CMND

Clearmind Medicine Inc.: Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial

Clearmind Medicine Inc. (Nasdaq: CMND) has enrolled the first patients with Alcohol Use Disorder (AUD) in its CMND-100 clinical trial. The trial, evaluating the safety and efficacy of CMND-100, is being conducted at Hadassah Medical Center in Jerusalem. The company aims to advance its psychedelic-based treatment for AUD, with plans to achieve key clinical milestones. Clearmind's shares are listed on Nasdaq under the symbol 'CMND'.

Original reporting
finanznachrichten.de
Published Sep 11, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 1:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$CMND
Bullish
medium confidence
Mentioned
$CMND
Relevance
8/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$CMNDBullishMed
01

Why it matters

The enrollment milestone reduces development risk and may attract investor interest, but actual stock movement will depend on trial data and regulatory feedback.

02

Market read

First‑in‑human enrollment for a novel AUD therapy is a material catalyst for CMND and may influence peer biotech valuations.

03

What to watch

Regulatory timeline and reimbursement landscape for psychedelic medicines remain uncertain.

Relevance 8/10Novelty 8/10Timing: today

Background

Clearmind Medicine is a clinical‑stage company developing non‑hallucinogenic psychedelic neuroplastogens for neuropsychiatric and addiction disorders.

Company-level read

Ticker impact

$CMNDBullishMedium confidence
Context

Clearmind Medicine announced the first enrollment of Alcohol Use Disorder patients in its CMND-100 trial.

Expected impact

Potential modest upside on positive interim data; downside risk if safety issues arise.

Evidence & confidence

Trial start is a key milestone for a clinical‑stage biotech; markets typically react positively to enrollment news, but impact depends on forthcoming data.

Market effects

Sector

Adds momentum to the psychedelic‑based neuroplastogen sector and may boost peer biotech valuations.

Regional

Positive signal for Canadian biotech pipeline; limited broader market effect.

Global

Highlights growing interest in non‑hallucinogenic psychedelic therapies worldwide.

Counterpoint

What could challenge this read

If early safety signals are negative, the enrollment could be a false positive for the stock.

Key entities

  • company
    Clearmind Medicine Inc.

    Clinical‑stage biotech developing CMND‑100 for Alcohol Use Disorder.

  • executive
    Adi Zuloff‑Shani

    CEO of Clearmind Medicine, quoted on trial progress.

Read at source← All news

Related articles

SEP 8
$CMNDMed

Clearmind Medicine Receives Yale IRB Approval For CMND-100 Trial

Clearmind Medicine (CMND) received Yale IRB approval to expand its Phase I/II trial for CMND-100, a treatment for alcohol use disorder. The trial will now include Yale School of Medicine, adding to sites like Johns Hopkins. CMND-100 showed positive safety results in earlier trials. CMND stock closed at $1.16, down 31.76%, and is trading at $1.12 premarket.

rttnews.com2 min
SEP 4
$CMNDMed

Clearmind Tumbles on Buying into Charging Robotics

Clearmind Medicine (CMND) agreed to buy a 51% stake in Charging Robotics, a wireless EV charging solutions provider, for $2.5M. The company will also lend Charging Robotics $1.5M at 4% interest. Charging Robotics' tech offers up to 10 kW continuous charging for automated parking and autonomous vehicles.

baystreet.ca1 min
SEP 1
$CMNDMedAI 8/10

Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled

Clearmind Medicine (CMND) has started Phase IIa of its trial for CMND-100, a treatment for Alcohol Use Disorder, with six patients enrolled. The trial is evaluating safety, tolerability, and preliminary efficacy. The company reported positive data from earlier trial phases, supporting continued development. CMND-100 is Clearmind's lead investigational psychedelic-based therapeutic.

sina.com.hk2 min
AUG 13
$CMNDMed

Clearmind Medicine Inc.: Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint

Clearmind Medicine (Nasdaq: CMND) said its independent DSMB approved advancing its FDA-regulated Phase I/II trial of CMND-100 for alcohol use disorder from Part A to Parts B and C. Part A met the primary safety endpoint in healthy participants. Part B will test 80 mg and 160 mg in AUD patients; Part C will test 160 mg in healthy participants.

finanznachrichten.de4 min
AUG 7
$MRNAMed

Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

rttnews.com7 min